Researchers have shown for the first time that a class of anti-fibrotic drugs inhibits the progression of interstitial lung disease (ILD) in people with rheumatoid arthritis (RA). Pirfenidone was shown to be safe and effective in these individuals, according to research conducted in part at National
Researchers have shown for the first time that a class of anti-fibrotic drugs inhibits the progression of interstitial lung disease in people with rheumatoid arthritis .
Rheumatoid arthritis is one of the most common autoimmune diseases in the world. The treatment for Rheumatoid Arthritis and Interstitial Lung Disease 1 was a randomized, double-blind, placebo-controlled phase 2 trial done in 34 academic centers specializing in ILD across four countries. Patients with RA-ILD were treated for 52 weeks with either pirfenidone, an anti-scarring medication, or a placebo.
While the trial was foreshortened because of recruitment challenges during the pandemic, the intervention appeared safe and in context, slowed the rate of forced vital capacity decline; as FVC decline is associated with early mortality, slowing the decline may be associated with longer life. “With this study, we are demonstrating that anti-fibrotics as a class of medications have a reproducible effect in reducing the rate of disease progression when measured by force vital capacity,” said Dr. Ivan Rosas, corresponding author of the paper, and professor of medicine and section chief of pulmonary, critical care and sleep medicine at Baylor College of Medicine. “This could have an impact on the overall survival of these patients.
Reference: “Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study” by Joshua J. Solomon, MD, Sonye K. Danoff, MD, Felix A. Woodhead, MD, Shelley Hurwitz, Ph.D., Rie Maurer, MD, Ian Glaspole, MD, Professor Paul F. Dellaripa, MD, Professor Bibek Gooptu, MD, Professor Robert Vassallo, MD, Professor P. Gerard Cox, MB, Professor Kevin R. Flaherty, MD, Huzaifa I.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Best Hospitals in the United States | WebMD Choice AwardsBest local hospitals for Oncology including treatments for leukemia treatment, breast cancer treatment, colorectal cancer treatment, lung cancer treatment, prostate cancer treatment, and skin cancer treatment in 2022.
Consulte Mais informação »
More vitamin D helps the brain function better, study findsA new study shows that the effects Vitamin D has on the brain are strong enough to help slow down brain diseases such as dementia.
Consulte Mais informação »
Alaska routinely doesn’t budget enough for wildfire response, study findsA new study looked at six states, including Alaska, and found that the actual costs of fighting wildfires are often obscured. The study’s author says that can be a problem when governments are deciding how much to spend on mitigation.
Consulte Mais informação »
Nationwide study finds Californians moving to wildfire-prone areas, favoring space, affordabilityA new University of Vermont study called 'Flocking to Fire' looks at migration patterns of people to wildfire-prone areas.
Consulte Mais informação »
Hearing Aids May Help You Avoid Dementia, Study FindsA systematic review of the scientific literature has found preliminary evidence that hearing aids could help keep the human brain young and fit as a person ages.
Consulte Mais informação »
A massive study finds genetic links to smoking and drinkingCarried out by dozens of authors, a new study evaluates information gathered from almost 3.4 million people, not all of European descent, and identifies thousands of genetic variants that are related to tobacco and alcohol consumption.
Consulte Mais informação »